Neurology Drugs Market Size, Share & Industry Analysis, By Indication (Alzheimer's Disease, Multiple Sclerosis, Epilepsy, Parkinson's Disease, and Others), By Drug Class (Cholinesterase Inhibitors, NMDA Receptor Antagonist, Antiepileptic Drugs, Immunomodulatory Drugs, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies), and Regional Forecast, 2025-2032

ATTRIBUTE

DETAILS

Study Period

2019-2032

Base Year

2024

Estimated Year

2025

Forecast Period

2025-2032

Historical Period

2019-2023

Growth Rate

CAGR of 6.3% from 2025-2032

Unit

Value (USD Billion)

Segmentation

By Indication

• Alzheimer's Disease
• Multiple Sclerosis
• Epilepsy 
• Parkinson's Disease
• Others

By Drug Class

• Cholinesterase Inhibitors
• NMDA Receptor Antagonist
• Antiepileptic Drugs
• Immunomodulatory Drugs
• Others

By Route of Administration

• Oral
• Parenteral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies & Drug Stores
• Online Pharmacies

By Region

• North America (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • U.S.
  • Canada
• Europe (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
• Rest of Middle East & Africa